Protocol 011 at Wk 144: Islatravir + Doravirine in Treatment-Naive Persons With HIV

October 27-30, 2021; London, United Kingdom
In the phase IIb trial, continued high rates of efficacy were seen in the combined ISL plus DOR arm at 144 Weeks; no participants in this arm met criteria for resistance testing.
Format: Microsoft PowerPoint (.ppt)
File Size: 219 KB
Released: November 3, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Expert HIV faculty analyze new data from CROI 2022, from Clinical Care Options (CCO)

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Jason E. Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRN Jasjit Gill, BSPharm, PharmD
Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 10, 2022 Expired: May 9, 2023

Expert selections of important HIV data from CROI 2022, including current and investigational strategies for prevention, ART, comorbidities, and cure

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Daniel R. Kuritzkes, MD
Released: May 2, 2022

Slides from Dr Michelle Collins-Ogle and Clinical Care Options (CCO): There are key HIV management considerations for pediatric patients

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS Released: April 29, 2022

Slides from Dr Michelle Collins-Ogle and Clinical Care Options (CCO): There are key HIV management considerations for transgender PWH

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS Released: April 29, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings